MENU
CABA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Cabaletta Bio (CABA) Ownership - Who owns Cabaletta Bio?
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases... Show more
Profile
Industry
N/A
Address
2929 Arch Street
Phone
+1 267 759-3100
Employees
103
Web
https://www.cabalettabio.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
55.82M
P/E Ratio
N/A
Total Cash
183.01M
Projected Growth
N/A
Total Debt
15.22M
Revenue
N/A
Risk (Beta)
3.79
Dividend Yield
N/A
Total Cash/Share
3.61
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
CABA
Capitalization
55.8M
P/E Ratio
N/A
Risk (Beta)
3.79
Dividend Yield
N/A
Total Cash
183M
Total Cash/Share
3.61
Total Debt
15.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
174M
P/B Ratio
0.37
Cash Flow
N/A
Earnings
-2.16
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
8.11
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-112.92M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-55.74
Shares Held By Institutions
134M
Shares Outstanding - Current
50.7M
Total Liabilities
30.2M
Total Volume MTD
N/A
Value
1
Gain YTD
-51.542
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
2929 Arch Street
Phone
+1 267 759-3100
Employees
103
Web
https://www.cabalettabio.com